TNFRSF4 and metastatic prostate carcinoma: A phase I and a phase I/II clinical trial testing an agonistic antibody against OX40 with cyclophosphamide and single fraction RT in metastatic prostate cancer (NCT01642290) and a OX40 agonist (MEDI6469) with different doses SBRT in metastatic breast cancer are currently active.